Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts...

詳細記述

書誌詳細

主要な著者:	Marina G. Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S. Moura, Walter P. Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson, Linda Wilhelm, Autumn Neville, Sasha Bernatsky
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-07-01
シリーズ:	Arthritis Research & Therapy
主題:	Rheumatoid arthritis Etanercept Remission induction Biosimilar pharmaceuticals
オンライン･アクセス:	https://doi.org/10.1186/s13075-025-03607-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!